| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.1K | 5.6% | 39.5% |
| Total Income | 1.1K | 4.1% | 38.0% |
| Expenditure | 989.90 | 5.4% | 43.3% |
| PBT | 147.40 | 3.5% | 10.7% |
| Net Profit | 112.30 | 3.4% | 10.0% |
| OPM | 16.55% | 0.16pp | 0.93pp |
| NPM | 9.87% | 0.77pp | 2.52pp |
| EPS | 4.67 | 3.5% | 9.6% |
Detailed report is being prepared.
Can Indegene sustain Q1's explosive growth as AI deals scale?
After a stellar Q1 (39.7% YoY growth, ₹10,631 Cr), Indegene reports Q2 results on Oct 29. The Street watches for sustained momentum and margin stabilization—the litmus test for whether AI-led pharma commercialization is a durable growth engine.
The bar is set: Revenue growth and margin trajectory
Q1 FY27 delivered ₹10,631 Cr (+39.7% YoY), with Enterprise Commercial Solutions the growth engine at +75.5% YoY. Management guided for EBITDA margin recovery to 18%+ by H2FY27, implying Q2–Q3 margins will remain under pressure from AI investments and scaling costs. Consensus FY27 revenue is ₹4,420 Cr (₹44.2b), which requires Q2–Q4 to average ~₹1,263 Cr/quarter. The setup: Q2 must show that Q1's momentum was not a one-quarter outlier—sustained 30%+ YoY growth and early signs of margin stabilization will validate the guidance path.
~₹10,800–₹11,200 Cr
35–40% YoY expected (Q1 was 39.7%). Sequential sequential moderation likely as large deals transition from ramp to steady-state execution
~₹800–₹850 Cr
60–65% YoY growth on-plan; Q1 was 75.5%, now lapping larger base. Trend matters more than rate
~₹270–₹290 Cr
Mid-20s% YoY growth expected; Q1 grew 24.7%. Steadiness here signals two-pillar diversification
~17–18%
Q1 saw compression from AI headcount and infrastructure investments. Recovery to 18%+ guidance targets H2; Q2 inflection is key watch
A strong quarter means revenue growth above 35% YoY, ECS momentum sustained >60%, and the earliest signs of margin stabilization (flat or +50 bps QoQ toward the 18% target). Client diversification trends (top client weak quarter is growth <30% YoY, ECS deceleration below 50%, or margins compressing further—red flags for execution challenges as outcome-based deals scale, or a loss of large-deal momentum.
What the Street is saying
Recent filings and corporate actions
1 · Frost & Sullivan 2026 Global Tech Leadership Award (Oct 22)
Indegene recognized for AI-powered pharma commercialization. No material financial impact; validates competitive narrative and likely supports equity story with institutional investors.
2 · Director resignation (Oct 15, effective Oct 29)
Mark Francis Dzialga resigned as Non-Executive Director due to Brighton Park Capital's shareholding sale. Routine governance transition. FII holding slipped 0.36pp YoY to 9.91%—mild pressure but no strategy shift.
3 · TCPA settlement ($4.72M, August 2026)
US subsidiary Indegene, Inc. settled class-action Telephone Consumer Protection Act lawsuit. One-time charge; immaterial to FY27 (~1–2 bps of consensus PAT). Likely already reflected in Q1 provisioning.
4 · German subsidiary merger (Sept 9, 2026)
Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting consolidated. Operational efficiency play; one-time restructuring cost expected to be minor.
5 · Digital Summit 2026 (late September)
Indegene held its 8th Digital Summit in Philadelphia; 120+ senior pharma leaders attended. Signals continued pipeline depth and customer engagement in the AI/pharma space.
Price action: Valuation setup
Indegene trades at ₹571.9 (Oct 23), below SMA20 (₹592.83) and SMA50 (₹586) but above SMA200 (₹520). RSI is neutral at 42.4; 52-week range ₹414–₹627; down 22% from ATH ₹736 but +38% off the 52-week low. Volume is normal. The Street's ₹605–620 targets imply a modest 5–8% near-term re-rate on a solid Q2; a major beat could push toward ₹650+, while a miss could test support at ₹540–550.
The line: What to watch on Oct 29
Indegene reports Q2 FY27 results on October 29, with the Board meeting to approve results. The stock is priced for a "good but not exceptional" quarter—stable growth and early margin stabilization. Three things determine the outcome: (1) Revenue growth sustainability—does Q2 hold above 35% YoY, or does the rate fade to Margin inflection visible—are EBITDA margins stabilizing at 17%+ or compressing further as AI investments weigh? (3) FY27 guidance—does management reaffirm the ₹4,420 Cr revenue and 19–20% Q4 margin targets, or trim?
If Q2 confirms the guidance path (growth >35%, margins stabilizing, FY27 ₹4.4b+ on track), the ₹605–620 Street target becomes a floor; a beat could trigger 10%+ upside. A miss—growth <30% or margin compression—would pressure the stock to ₹540–550 and force a guidance reset. Outcome-based contract profitability and client concentration (top client now at 9%) are secondary watches but matter for the bull thesis.